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Abstract
Background: RNA interference is an evolutionary conserved immune response mechanism that
can be used as a tool to provide novel insights into gene function and structure. The ability to
efficiently deliver small interfering RNA to modulate gene expression in vivo may provide new
therapeutic approaches to currently intractable diseases.
Methods: In vitro, siRNA targeting IL-12p40 was delivered to the murine macrophage cell line
(J774A.1) encapsulated in a liposome with an IL-12 inducing agent (LPS/IFN-γ) over a number of
time points. Controls included a variety of non-target specific siRNA reagents. Supernatants were
analyzed for cytokine production while the cells were removed for mRNA profiling.
In vivo, siRNA-targeting IL-12p40 was delivered to the murine peritoneal cavity in a therapeutic
fashion, after endotoxin (LPS) challenge. Cells from the peritoneal cavity were removed by lavage
and analyzed by flow cytometry. Levels of IL-12 present in lavage and in serum were also examined
by ELISA.
Results:  In this report, we show that IL-12p40 siRNA can specifically silence macrophage
expression of IL-12p40 mRNA and IL-12p70 protein in vitro. We extend this finding to demonstrate
that delivery of liposome encapsulated siRNA targeting IL-12p40 to the murine peritoneal cavity
can modulate an inflammatory stimulus in vivo. Furthermore, specific siRNA can be used
therapeutically after endotoxin challenge to reduce both the local and systemic inflammatory
response. Thus, the delivery of siRNA can be used to elicit specific non-permanent inhibition of
endogenous protein expression.
Conclusion:  In vitro silencing of IL-12p40 using siRNA at selected doses leads to specific
knockdown of IL-12p70 protein production without inducing type I interferons. Furthermore,
siRNA targeting murine IL-12p40 can be used therapeutically to counter an inflammatory response
in vivo.
Background
RNA interference (RNAi) is an evolutionary conserved
sequence-specific RNA silencing mechanism found as an
anti-viral response in invertebrates, plants and mamma-
lian cells [1]. Although the mechanism of silencing is not
completely understood, the basic premise of RNAi rests
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on the ability of double stranded RNA (dsRNA) to specif-
ically degrade homologous messenger RNA (mRNA). The
RNAi pathway is triggered in mammalian cells by the
presence of dsRNA or in the presence of short 19–22nt
dsRNA fragments termed small interfering RNA molecules
(siRNA). siRNA molecules activate an RNA-induced
silencing complex (RISC) that unwinds the siRNA duplex
[2]. The specificity of locus degradation is guided by the
antisense strand of the unwound siRNA, followed by
sense strand siRNA binding to the complementary mRNA
site for cleavage by RISC. The cleavage of the sense strand
siRNA and target mRNA results in the self-amplifying pro-
duction of new siRNA intermediaries that continue
mRNA target degradation in an ATP dependent manner
[3,4]. This phenomenon means that low doses of siRNA
can be more effective than antisense therapy. Further-
more, this approach is preferable to gene and antisense
based therapies, in that siRNA is non-heritable and does
not require adenoviral vectors, which limit the effective-
ness and acceptability for use in children.
RNAi can be exploited as a tool to provide novel insights
into gene function and structure. The capacity to effi-
ciently deliver siRNA to modulate gene expression in vivo
may provide new therapeutic approaches to currently
intractable diseases. Like other new genetic technologies,
siRNA gene suppression faces several methodological lim-
itations in vivo. Foremost among these are the efficient
delivery of siRNA to target cells [5,6], non-specific effects
of putative control duplexes [7-9] and the potential thera-
peutic problems of viral expression vectors [10]. One
approach to overcoming these obstacles is to deliver non-
heritable siRNA duplexes in a model system and monitor
the influence upon experimentally induced inflamma-
tion. This approach would provide a method that allows
the rapid screening of what have been termed "druggable"
targets [11].
Interleukin-12 (IL-12p70) is a cytokine with a well-char-
acterized pro-inflammatory function [12] that has been
suggested as a target for therapeutic intervention [13-15].
Bioactive IL-12p70 is a heterodimer formed by a heavy
chain (p40) and a light chain subunit (p35), encoded by
two separate genes whose expression is independently
regulated at the transcriptional level [16]. The p35 sub-
unit is constitutively expressed at low levels in most cell
types but is up regulated during cell activation. In con-
trast, the IL-12p40 gene is under tight transcriptional con-
trol only expressed in macrophages or other APC
following activation by microbial products [17]. Produc-
tion of IL-12p70 is enhanced by IFN-γ via the IFN consen-
sus sequence binding protein [18] but reduced by IL-10
[19].
IL-12p70 has pleiotropic effects on target cells but the
major role is as a pro-inflammatory cytokine in cell medi-
ated immunity against microbial insult. In particular IL-
12p70 acts upon T and NK cells to increases cytokine pro-
duction, proliferation, and cytotoxicity, functions that
become evident several hours after exposure to infections
agents [19]. The IFN-γ subsequently produced, potentiates
antigen presentation functions important in clearing
infectious agents. These functions include increased co-
stimulatory molecule expression, phagocytosis, and pro-
duction of reactive oxygen and nitrogen intermediates
[19,20]. However, IL-12p70 is not always protective or
beneficial, indeed a variety of pathological conditions,
including sepsis, are associated with IL-12 driven pathol-
ogy [21,22]. In addition to the well-characterized role of
IL-12p70, it is now known that the IL-12p40 subunit is
also biologically active. This subunit may act to antago-
nize the heterodimer function [23], or may have a broader
direct role, less dependent on IL-12p70 [24,25].
In order to explore the therapeutic feasibility of RNA inter-
ference, we used siRNA to specifically ablate IL-12p40
expression in vitro and in vivo. This approach extends the
power of RNA interference to gene expression studies in
live animals without the use of genetic engineering, plas-
mid DNA reporter systems [2,26] retroviral [27,28] or len-
tiviral siRNA expression vectors [29] and opens the way
for exploring the use of siRNA in humans to treat disease.
Our results provide a description of siRNA mediated sup-
pression of an endogenous immune gene in vivo and
describe a novel therapeutic and research approach for
gene specific inhibition of an important cellular and
immunological response.
Materials and Methods
Mice & Cell Lines
Female BALB/c mice (Harlan Limited, Bicester, UK) and
IL-12p40 gene-disrupted mice (IL12p40-/-) (Jackson Lab-
oratories, Bar Harbor, Maine) were maintained under the
guidelines of the Irish Department of Health and the local
bioethics committee. All mice were 12–14 weeks old at
the initiation of experiments and sacrificed on comple-
tion. The murine macrophage cell line (J774A.1) was used
to investigate silencing of IL-12p40 cytokine gene
expression.
Preparation of siRNA
siRNA oligonucleotides with the following sense and anti-
sense sequences were designed from the GenBank reposi-
tory: accession number; NM_008352, Mus musculus
interleukin 12b (IL12b), mRNA. IL-12p40 siRNA 5'-C
CUC ACC UGU GAC ACG CCU dTdT-3' (sense) and 3'-
dTdT G GAG UGG ACA CUG UGC GGA-5' (antisense);
Mutant siRNA 5'-C CUC ACC UUC GAC ACG CCU dTdT-
3' (sense) and 3'-dTdTG GAG UGG AAG CUG UGC GGA-Journal of Inflammation 2004, 1:4 http://www.journal-inflammation.com/content/1/1/4
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5' (antisense); GFPsiRNA 5'-GGC UAC GUC CAG GAG
CGC ACC dTdT-3' (sense) and 3'-dTdT CCG AUG CAG
GUC CUC GCG UGG-5' (antisense). The antisense of the
IL-12p40 siRNA duplex (As.RNA) was also used as a con-
trol for in vivo experiments. Each complementary RNA
strand was deprotected according to manufacturer's
instructions. For the production of the IL-12p40 siRNA
duplex, sense and antisense siRNA strands were mixed in
equimolar ratios and treated by heating to 95°C for 1 min
followed by annealing at 37°C for 1 h and allowed to cool
slowly overnight to room temperature. All siRNA oligonu-
cleotides were synthesized commercially (Dharmacon,
Lafayette, CO) using 2'ACE protection chemistry.
In vitro siRNA interference
Semi-confluent J774A.1 cells were cultured at 1 × 105
cells/ml in antibiotic free, 8% (v/v) endotoxin-low fetal-
calf serum RPMI (Gibco-Invitrogen, Paisley, UK) contain-
ing L-glutamine (Sigma, Poole, UK) 12–16 h before trans-
fection. For siRNA transfections 3 µl of a 20 µM siRNA
duplex (target or control) solution was mixed with 47 µl
of Opti-mem (Gibco-Invitrogen). In a second tube 3 µl of
oligofectamine (Gibco-Invitrogen) was mixed with 12 µl
of Opti-mem and incubated at room temperature for 15
min. Solutions were combined for 40 min and brought to
a final volume of 100 µl. The expression of IL-12p40
mRNA and IL-12p70 protein was induced by the addition
of 1 µg/ml E. coli LPS Serotype 0111:B4 (Sigma) and 10
ng/ml rIFN-γ (Pharmingen, San Diego, CA.), for the last
12 h of each culture post siRNA transfection.
RNA isolation and semi-quantitative RT-PCR (sqRT-PCR)
Total cellular RNA was isolated from J774A.1 cells from in
vitro  experiments with TRIZOL Reagent (Gibco-Invitro-
gen) following the manufacturer's protocol and quanti-
fied by spectrophotometry. RNA was reverse transcribed,
and 100 ng of the complementary DNA product ampli-
fied by PCR as previously described [51] using 60 ng of
gene specific upstream and downstream primers. Murine
β-actin product was used to normalize RNA samples. PCR
conditions included a pre-incubation at 95°C for 5 min
followed by 35 amplification cycles (95°C, 1 min; 1 min
at annealing temperature; 2 min at 72°C, and a final 10
min at 72°C). Upstream and downstream primers for IL-
12p40 were specifically designed to flank the IL-12p40
siRNA target region; sense, 5'-AAACAGTGAACCTCACCT-
GTGACAC-3' ; antisense, 5'-TTCATCAGCAAGTTCTT-
GGGCG-3'. PCR products were visualized by UV
illuminated agarose gel electrophoresis.
In vivo siRNA interference
Control mice (BALB/c & IL12p40-/-) received 200 µl Opti-
mem intra-peritoneal (i.p.) containing oligofectamine
alone. In addition LPS positive control mice received 1 µg
E. coli LPS. For each experimental administration, 10 µl
siRNA duplexes (IL-12p40 or controls at equimolar con-
centration) were premixed with 40 µl of Opti-mem. Sepa-
rately, 6 µl of oligofectamine was mixed with 24 µl of
Opti-mem and incubated at room temperature for 15
min. These solutions were mixed at room temperature for
40 min. For co-injection experiments, these were com-
bined with LPS (1 µg/mouse) and formulated as above.
For therapeutic silencing, mice received 1 µg LPS, in the
absence of siRNA duplexes, 1 h prior to administration of
siRNA (IL-12p40 or controls) as above. At various time
points, blood serum, peritoneal cells or lavage fluid were
sampled for further analysis.
Peritoneal Lavage & Serum preparation
Peritoneal cells were harvested by washing the peritoneal
cavity with 1 ml of sterile PBS. This was centrifuged for 5
min at 400 g, lavage supernatant was removed for analysis
and cells analysed by flow cytometry. Serum was prepared
by cardiac puncture. Sera and lavage supernatants were
assayed without delay or storage.
Flow Cytometry
Phenotypic analysis of siRNA-transfected cells was per-
formed using a FACScalibur™ with associated Cellquest™
software (Becton Dickinson, San Jose, CA). Forward and
side scatter were measured from peritoneal lavage prepa-
rations at 12, 24 and 48 h in response to simultaneous
delivery of IL-12p40 siRNA and LPS, and at 24 h for those
mice receiving therapeutic IL-12p40 siRNA post LPS
administration. Cell surface marker analysis of CD11b,
CD14, CD40, CD80, CD86, F4/80 and MHC class II by
J774A.1 cells was performed as previously described [52],
control samples included cells incubated with isotype
matched, directly conjugated, control antibodies as
appropriate.
Analysis of cytokine production
Cytokine production from in vitro experiments was
assayed using commercially available immunoassays for
mouse IL-12p70, IFN-γ, IFN-β, IL-10, and IL-4 (Pharmin-
gen). Mouse IL-12p40 in blood serum and peritoneal lav-
age fluid was assayed using murine IL-12p40 ELISA (R&D
systems, Abingdon, UK) according to the manufacturer's
instructions.
Statistical analysis
One-way ANOVA was used to determine significance of
cytokine production between groups; post test analyses
were not performed. The student t-Test was used to deter-
mine the significance of different fluorescent intensities
obtained by flow cytometry.Journal of Inflammation 2004, 1:4 http://www.journal-inflammation.com/content/1/1/4
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siRNA interference of IL-12 transcription and translation in vitro Figure 1
siRNA interference of IL-12 transcription and translation in vitro. J744A.1 cells were transfected with IL-12p40 siRNA for differ-
ent periods (24–72 h). For the last 12 h of culture, cells were stimulated with LPS/IFN-γ or with PBS (-LPS, hereafter termed 
unstimulated). Expression of IL-12p40 (A) was determined by sqRT-PCR. Samples were normalized for β-actin expression 
(lower panel A). Control siRNA transfections included naked siRNA for IL-12p40, mutant siRNA for IL-12p40 and GFP (B). IL-
12p70 protein expression was determined by ELISA (C). Data are representative of at least four independent experiments; IL-
12p70 protein concentration is expressed as the mean (+/-SEM) from triplicate cultures (n = 3) on each occasion.Journal of Inflammation 2004, 1:4 http://www.journal-inflammation.com/content/1/1/4
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Results
IL-12 p40 siRNA knocks down IL-12 expression in vitro
To investigate silencing of cytokine gene expression in
vitro, the murine macrophage-like cell line J774A.1 was
transiently transfected with siRNA targeting IL-12p40 for
the time points shown in Fig. 1 (24, 48, 72 h). These cells
were stimulated for the final 12 h of each experiment,
with LPS and IFN-γ (LPS/IFN-γ), a protocol that induces
IL-12p70 [30]. Transfection with IL-12p40 siRNA resulted
in a significant suppression of p40 mRNA and a conse-
quent loss of detectable IL-12p70 in cell culture superna-
tant (Fig. 1A,1B,1C). A reduction in IL-12p40 mRNA was
observed at 24 h, but silencing was more pronounced at
48 h. Transfection for 72 h with IL-12p40 siRNA was infe-
rior to either 24 or 48 h, as IL-12p40 mRNA expression
and IL-12p70 protein synthesis began to recover by this
time (Fig. 1A &1C). Thus siRNA silencing was transient in
this system. Control siRNA transfections included siRNA
for IL-12p40 without transfection agent (naked siRNA),
siRNA for IL-12p40 where the 10th and 11th bases were
reversed (mutant siRNA), and siRNA targeting GFP, a pro-
tein that does not naturally occur in J774A.1 cells. These
control siRNAs did not induce IL-12p40 mRNA expres-
sion (Fig. 1B). Our results show sequence-specific siRNA
mediated inhibition of IL-12p40 mRNA synthesis in vitro
at 48 h post siRNA incubation (Fig. 1A). ELISA confirmed
the siRNA mediated silencing of IL-12p70 protein expres-
sion (Fig. 1C), reflecting the significant inhibition of IL-
12p40 mRNA synthesis (p < 0.001, compared to LPS/IFN-
γ group). Supernatants from unstimulated cells, or cells
incubated with control siRNAs, showed no IL-12p70 pro-
tein production. Suppression of IL-12p70 was transient,
with levels recovering at the remaining time points.
mRNA expression profiling for the inflammatory
cytokines IFN-β, IL-12p35, IL-23p19, IL-6, IL-10 and IFN-
γ in IL-12p40 or control silenced cells, showed no non-
specific siRNA silencing at the doses employed (Table 1).
Control siRNA delivered by the same protocol did not
induce mRNA for IFN-β, IL-12p35, IL-23p19, IL-6, IL-10
and IFN-γ. Likewise, cells transfected with IL-12p40 siRNA
showed no modulation of the protein levels of IL-4, IL-5,
IL-6, IL-10, and TNF-α (results not shown). One cytokine
did not follow this pattern. Although IL-12p40 siRNA
transfection of stimulated macrophages did not result in a
detectable reduction of IFN-γ mRNA (Table 1 and Fig.
2A), a reduction of detectable IFN-γ protein was observed
(Fig. 2B). This discrepancy between IFN-γ mRNA and pro-
tein detection may reflect the role of IL-12p40 in post-
transcriptional regulation of IFN-γ secretion [31] and is
consistent with the timing of IFN-γ protein synthesis and
secretion previously observed in LPS challenged IL-12p40-
/- mice in vivo [32].
Silencing IL-12p40 reduces LPS/IFN-γ driven macrophage 
activation in vitro
To determine whether silencing IL-12p40 had broader
effects on macrophages, the expression of the activation/co-
stimulatory markers CD40, CD80, CD86, and MHC class II
was examined following simultaneous exposure of J774
cells to LPS/IFN-γ and either control or IL-12p40-specific
siRNA. Expression of CD14, a component of the LPS recog-
nition machinery was also examined. LPS/IFN-γ stimula-
tion alone (24 h) resulted in increased CD40, CD86 and
MHC class II expression (Table 2), but had no effect on
CD80 or CD14 as expected. IL-12p40-specific siRNA did
not activate macrophages in the absence of LPS/IFN-γ
(Table 2). In the presence of LPS/IFN-γ, siRNA targeting IL-
12p40 prevented increased expression of CD40, and CD86,
suggesting that silencing IL-12 interfered with macrophage
activation. The expression of CD80, CD14 and MHC class
II were not affected (Table 2). In contrast, Mut.siRNA did
not prevent CD86 upregulation when cells were stimulated
with LPS/IFN-γ but rather resulted in increased expression,
suggesting that this sequence may contribute to macro-
phage activation not seen with IL-12p40 specific siRNA.
The expression of the macrophage phenotypic markers
CD11b and F4/80 were unchanged in all experiments, no
significant difference was seen in levels of apoptosis
between groups (data not shown).
Table 1: IL-12p40 siRNA specifically silences mRNA for IL-12p40 
and not other cytokines.
Target Silencing by treatmenta
LPS/IFN-γ:- + +
SiRNA: IL-12p40 Mut.siRNA IL-12p40
β-Actin - - -
IL-12p40 - - +
IL-12p35 - - -
IL-23p19 - - -
IFN-γ ---
IFN-β ---
TNF-α ---
IL-4 - - -
IL-5 - - -
IL-6 - - -
IL-10 - - -
aJ774 cells were incubated with or without LPS/IFN-γ and specific or 
control siRNA as described in the materials and methods section. 
mRNA for different targets were detected by sqRT-PCR. In this table 
silencing (+) is defined as the loss of a visible band from stimulated 
cultures; the - symbol indicates either no loss of a visible band from 
stimulated (siRNA + LPS/IFN-γ) cultures, or no visible alteration 
(induction or loss) in unstimulated (siRNA – LPS/IFN-γ) cultures. All 
results represent at least two experiments performed in triplicate.Journal of Inflammation 2004, 1:4 http://www.journal-inflammation.com/content/1/1/4
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Silencing IL-12p40 influences IFN-γ protein expression. Figure 2
Silencing IL-12p40 influences IFN-γ protein expression. The influence of silencing IL-12p40 on the expression of IFN-γ was 
determined using the conditions described in Fig. 1, by sqRT-PCR for IFN-γ mRNA (A) or by ELISA for IFN-γ protein present 
in culture supernatant (B). Data are representative of at least four independent experiments; IFN-γ protein concentration is 
expressed as the mean (+/-SEM) from triplicate cultures (n = 3) on each occasion. Levels of IFN-γ are significantly reduced in 
the presence of IL-12p40 siRNA for 24, 48, and 72 h (p < 0.0001) when compared to stimulated non-silenced cultures.
Table 2: LPS/IFN-γ driven macrophage expression of CD40 and CD86 is modulated by IL-12p40 siRNA.
Treatment Mean Fluorescent Intensity (+/-SEM)
LPS/IFN-γ siRNA CD40 CD86 CD80 CD14 MHCII
- - 22 (5) 9 (4) 34 (8) 44 (11) 19 (8)
- IL-12p40 16 (9) 14 (1) 29 (2) 49 (4) 18 (8)
+ - 290 (27) 41(5) 102 (21) 86 (11) 46 (5)
+ IL-12p40 94 (17)* 7 (1)* 66 (13) 47 (9) 46 (5)
+ Mut.siRNA 241 (18) 72 (6) 102 (4) 86 (16) 43 (5)
Data are the mean ± SEM to nearest whole number of MFI of 3 independent experiments, each performed in triplicate (n = 3), * statistical 
significance (α = 0.05) compared to cells stimulated with LPS/IFN-γ in the absence of IL-12p40 siRNA.Journal of Inflammation 2004, 1:4 http://www.journal-inflammation.com/content/1/1/4
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siRNA targeting IL-12p40 specifically reduces LPS driven 
inflammation in vivo
We investigated the possibility of silencing IL-12 by RNA
interference  in vivo, using a well-established murine
model of LPS driven peritoneal inflammation [33,34].
The delivery of LPS i.p. resulted in increased activated
phagocytic cells detectable at 12, 24 and 48 h by lavage,
compared to controls (Fig. 3A groups I & II). This effect
was greatly reduced in IL-12p40-/- mice. Simultaneous
delivery of a control irrelevant siRNA (GFPsiRNA) or a
mutant IL-12p40 siRNA (Mut.siRNA) duplex containing
two mismatches to the IL-12p40 specific sequence had no
influence on LPS driven inflammation. Likewise, a control
siRNA that was the antisense of the functional duplex
(As.siRNA) did not result in a significant reduction in the
level of activated phagocytic cells. However, delivery of IL-
12p40 siRNA dramatically reduced the levels of inflam-
mation (Fig. 3A) at 12, 24 and 48 h. Delivery of encapsu-
lated siRNA did not result in increased in cell death of
peritoneal cells (apoptosis or necrosis) compared to con-
trols at the time points selected (data not shown).
Control wildtype and IL-12p40-/- mice showed no inflam-
matory response to siRNA transfection reagents alone (Fig.
3). LPS challenged wildtype mice, and mice co-challenged
with control siRNAs displayed a typical inflammatory cell
response in the peritoneal cavity with increased numbers of
activated phagocytic cells, at 24 h (19.8%, 16.8 %, 22.01%)
and 48 h (22.53%, 17.95% 16.64%) compared to control
unchallenged mice (2.17% and 3.46%). Similar results
were observed in mice co-challenged with LPS and
As.siRNA at 24 and 48 h (18.9% and 23.64% respectively).
However, mice co-administered LPS and specific IL-12p40
siRNA displayed reduced numbers of activated cells
(6.3%), mirroring the reduced inflammatory response seen
in LPS challenged IL-12p40-/- mice (7.3%) at 24 h. How-
ever, modulation of the inflammatory response in the LPS-
IL-12p40 siRNA challenged mice was not permanent. An
increase in activated phagocytic cells (11.10%) was seen at
48 h, although levels were still lower than the LPS chal-
lenged BALB/c mice (22.53%), (Fig. 3A &3C). Thus, siRNA-
mediated silencing of IL-12p40 mRNA in this model has a
significant but non-permanent effect on the ability to medi-
ate a response to LPS challenge in vivo.
siRNA targeting of the proinflammatory cytokine IL-12p40 
can be used as a therapeutic intervention against 
inflammation driven by microbial products
In order to explore the potential use of siRNA in a more
therapeutic context and based on the findings above, we
delivered IL-12p40 siRNA by direct injection into the
peritoneal cavity, 1 h post LPS challenge. Administration
of IL-12p40 siRNA post LPS challenge (Fig. 3B I-VI)
resulted in a decrease in the number of activated phago-
cytic cells, (4.22%) at 24 h, when compared to mice
receiving LPS only (16.64%), control siRNAs (Mut.siRNA
and GFPsiRNA) or As.siRNA, (25.03%, 17.07% and
12.63% respectively). These data demonstrate that IL-
12p40 siRNA can be used therapeutically to specifically
silence a cytokine-driven inflammatory response in vivo, if
delivered at a suitable moment.
In parallel experiments, the local and systemic effects of
siRNA mediated silencing were assessed. IL-12p40 siRNA
co-delivered with LPS or administered post LPS insult, had
both local and systemic anti-inflammatory effects (Fig. 4).
Control BALB/c mice given siRNA transfection reagents
alone, showed low levels of IL-12p40 protein expression in
blood serum and peritoneal lavage samples (103 pg/ml
and 75 pg/ml respectively). However, mice challenged with
LPS, or co-challenged with LPS and control siRNAs (GFP-
siRNA, Mut.siRNA)(Fig. 4) showed significant increases in
IL-12p40 protein detected in both serum and lavage com-
pared to control (p < 0.05). Delivery of As.siRNA did result
in reduced serum IL-12p40 protein but only when admin-
istered therapeutically (Fig. 4B). Strikingly, delivery of IL-
12p40 siRNA delivered simultaneous to, or 1 h post LPS
administration, resulted in a significant reduction in the
levels of IL-12p40 protein detected in all serum and perito-
neal lavage samples compared to LPS alone (p < 0.05, in
each case) (Fig. 4). Delivery of negative control siRNAs
showed no such reduction. Our findings demonstrate that
well designed sequence specific siRNA can provide a signif-
icant therapeutic effect and elicit local and systemic protec-
tion against inflammation.
Discussion
The ability to efficiently deliver small interfering RNA to
modulate gene expression in vivo may provide new
therapeutic approaches to currently intractable diseases.
We initially demonstrate that in vitro IL-12p40 siRNA spe-
cifically silenced its mRNA homologue leading to tran-
sient silencing of IL-12p40 protein and consequent
knockdown of IL-12p70 expression. This approach did
not target other proinflammatory cytokines (IL-6, IL-23,
IL-10, TNF-α), for RNA-induced gene silencing, nor did
control siRNA induce these cytokines or type I interferon
at the concentrations employed. Furthermore, we demon-
strate that this approach can be extended in vivo by show-
ing that silencing of IL-12p40 results in the non-
permanent suppression of IL-12 in a murine model of
peritoneal inflammation. Such silencing is evident in the
reduced levels of IL-12 detectable locally in peritoneal lav-
age and systemically in blood serum. Finally, we show
that siRNA can be used therapeutically after the initiation
of an inflammatory response to knockdown IL-12 expres-
sion and to reduce the observed inflammatory infiltrate
seen in this model.Journal of Inflammation 2004, 1:4 http://www.journal-inflammation.com/content/1/1/4
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Silencing of IL-12 by siRNA interferes with the inflammatory response in vivo Figure 3
Silencing of IL-12 by siRNA interferes with the inflammatory response in vivo. siRNA was delivered with LPS (A) or therapeuti-
cally 1 h post LPS stimulation (B). Mice received transfection reagents only (no siRNA) (group I), LPS alone (group II) or were 
co-injected with LPS and control siRNAs (group III-V, As.siRNA, GFPsiRNA, and Mut.siRNA respectively) or LPS and IL-12p40 
specific siRNA (group VI). Inflammation was characterized by flow cytometry of peritoneal lavage at 12, 24 and 48 h. The typi-
cal inflammatory cell response in the peritoneal cavity is shown in the enclosed region. Control IL-12p40-/-mice showed the 
characteristic germ-line knockout response to LPS throughout the experiment (group VII). IL-12p40 siRNA was also delivered 
therapeutically (B) 1 h post LPS challenge, and inflammation measured at 24 h. Mice receiving control siRNAs (groups III-V) dis-
played a similar inflammatory response to mice receiving LPS insult alone (group II). Mice receiving IL-12p40 siRNA (group VI) 
displayed a reduced number of activated phagocytic cells at the same time point (enclosed region). Data are representative of 
at least three independent experiments (Groups I-VI) or two experiments (Group VII). In each experiment, n = at least 4 mice 
on each occasion. The absolute numbers of cells present in lavage fluid, represented by the enclosed region in A, are illustrated 
(C). Data in bar charts represent the mean number of cells (+/-SEM)/ml lavage fluid from four mice at the time points indicated.Journal of Inflammation 2004, 1:4 http://www.journal-inflammation.com/content/1/1/4
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siRNA silencing IL-12p40 reduces local and systemic levels of IL-12p40 protein Figure 4
siRNA silencing IL-12p40 reduces local and systemic levels of IL-12p40 protein. LPS delivery to the peritoneal cavity with simul-
taneous (white bars), or therapeutic administration (black bars) of IL-12p40 specific siRNA reduced the appearance of IL-
12p40 protein in serum (A) and peritoneal lavage (B) as measured by IL-12p40 specific ELISA. Serum and lavage were sampled 
at 6 h post LPS challenge. IL-12p40 observed in serum or lavage from LPS challenged mice or mice co-challenged with LPS and 
either GFPsiRNA or Mut.siRNA was significantly greater than control (p < 0.05, in both cases). IL-12p40 siRNA when deliv-
ered simultaneously or therapeutically significantly reduced IL-12p40 protein production compared to LPS challenge alone (p < 
0.05, in each case). Data are representative of three independent experiments where n = 4 on each occasion; IL-12p40 protein 
concentration is expressed as the mean (+/-SEM) from triplicate samples.Journal of Inflammation 2004, 1:4 http://www.journal-inflammation.com/content/1/1/4
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IL-12 is a key factor in the early inflammatory response
and in the subsequent development of type 1 responses
[35]. A variety of signals can stimulate macrophages
resulting in increased surface expression of CD40 and the
B7 family member CD86 as well as activation of the cell's
antimicrobial machinery [20,36]. Here, we show that
silencing of IL-12p40 interferes with endotoxin mediated
activation as measured by CD40 and CD86 expression,
similar to that seen in IL-12p40-/- mice in which macro-
phages adopt the so-called M2 profile [37]. Taken
together, these data support the hypothesis that IL-12p40
has a central role in driving macrophage polarization, and
regulating the intrinsic ability to respond to immunologi-
cal insult [30,37]. The polarization of CD4+  T-cell
cytokine production towards type 1 or type 2 responses
following immunological insult is controlled by a
number of factors, including the nature of the immuno-
gen, route of immunization, the APC and the regulatory
cytokine milieu at the site of T-cell stimulation [38,39]. IL-
12 induces the secretion of IFN-γ by NK and CD4+ T-cells,
promoting the differentiation and development of Th1
cells from Th0 precursors [40,41]. Th1 cells play an
important role in the resolution of infections with intrac-
ellular organisms, IL-12 influences the course of bacterial,
viral, and parasitic infections by altering the balance of
Th1 and Th2 cells in favour of IFN-γ production [42,43].
The ability to transiently silence IL-12 may therefore be a
useful research tool to dissect the development of polar-
ized immune responses in a variety of infectious diseases.
Although IL-12p40 as a component of IL-12p70 is known
to have a direct role in macrophage activation [36,44], it
has recently become clear that IL-12p40 has a role inde-
pendent of the heterodimer [24]. IL-12p40 acts as an
antagonist of IL-12p70 function [23], but also has direct
effector function [25,45]. In particular IL-12p40 plays a
role in macrophage, but not NK or T-cell recruitment and
chemotaxis to inflammatory sites [25,45]. The silencing of
IL-12p40, and subsequent reduced inflammation seen in
vivo during the present study supports a broader role for
IL-12p40 in macrophage recruitment to sites of inflam-
mation induced by microbial stimuli. Silencing IL-12p40
in vitro did not result in non-specific silencing of IL-
12p35, IL-23p19, IL-10, TNF-α, IL-6 or IFN-γ mRNA.
However, silencing of IL-12p40 by siRNA did result in a
reduction of IFN-γ production detected by ELISA. Regula-
tion of IFN-γ production by macrophages has not been
extensively studied, however it has been shown that in
some cell types IL-12 promotes nuclear localization of
IFN-γ mRNA and exerts post-transcriptional control over
IFN-γ secretion [31]. Our observations are consistent with
this finding and suggest that IL-12 may exercise post-tran-
scriptional control on IFN-γ protein production in
macrophages.
Non-specific immune stimulation is an undesirable side
effect of antisense oligonucleotides and vector based
expression approaches in vivo [8,46]. Recently Sledz et al.,
(2003) have found that under some conditions transfec-
tion of siRNA results in IFN-mediated activation of the
JAK-STAT pathway and global upregulation of IFN-stimu-
lated genes. To demonstrate specificity of gene suppres-
sion, and non-activation of the IFN immune response in
our study, three siRNA duplexes were designed according
to Semizarov et al. [46]. We employed three different con-
trol siRNAs; a mutant IL-12p40 siRNA (Mut.siRNA) with
two point mutations at the 10th and 11th nucleotide of the
IL-12p40 siRNA duplex, an irrelevant siRNA duplex (GFP-
siRNA) [26] and also the antisense of the siRNA duplex
(As.siRNA). At the concentrations employed in this study
we saw no non-specific silencing from control siRNA and
notably no induction of IFN-β.
The ability to silence an inflammatory mediator in vivo
has implications for the application of siRNA approaches
in inflammatory diseases such as sepsis, acute respiratory
distress syndrome, and T-cell mediated autoimmune dis-
eases where the transient suppression of inflammatory
gene expression would be likely to prove beneficial [47].
We demonstrate that delivery of liposome-encapsulated
siRNA targeting IL-12p40 to the murine peritoneal cavity
can moderate an inflammatory stimulus in vivo. To date
there have been very few demonstrations of siRNA efficacy
in vivo. It has been shown that intravenous injection of Fas
siRNA specifically reduced Fas mRNA levels and expres-
sion of Fas protein in mouse hepatocytes [6]. More
recently Sorensen et al, reported siRNA mediated TNF-α
protein ablation in vivo [48]. Using a similar delivery tech-
nique, our study greatly expands the use of siRNA as a
pharmaceutical tool for drug discovery by demonstrating
that i.p. delivery inhibits endogenous gene expression
affecting detectable cytokine levels both locally and sys-
temically, resulting in altered cell activation and matura-
tion during inflammatory insult. This supports the
findings of Song et al, who showed that treatment with
Fas siRNA 2 days prior to mitogen challenge abrogated
hepatocyte necrosis and inflammatory infiltration result-
ing in reduced serum concentrations of transaminases [6].
We investigated whether IL-12p40 specific siRNA could
be used therapeutically after endotoxin challenge to
reduce both the local and systemic inflammatory
response. Our results show delivery of IL-12p40 siRNA
provides local and systemic anti-inflammatory effects on
IL-12p40 protein levels. Thus, the delivery of siRNA can
be used to elicit specific, non-permanent, inhibition of
endogenous protein expression after exposure to inflam-
matory insult.
The simplicity of this approach provides a rapid means to
elucidate novel druggable targets in formerly intractableJournal of Inflammation 2004, 1:4 http://www.journal-inflammation.com/content/1/1/4
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inflammatory and immune-mediated diseases. Impor-
tantly, the transient and specific silencing of protein prod-
ucts may prove advantageous. Permanent gene silencing
through the use of plasmid DNA reporter systems [2,26]
retroviral [27] or lentiviral expression vectors [29] have a
number of disadvantages. Permanent silencing of
immune mediators may leave the host susceptible to sub-
sequent infection, or set up potentially pathological
hyper-responsiveness. Furthermore, there are unresolved
safety issues relating to gene integration and host cell
transformation that render these approaches less accepta-
ble for use in children. The use of non-heritable siRNA
delivered by liposomes circumvents these problems and
opens the way for exploring the use of siRNA in humans
to treat disease.
Our findings show that synthetic siRNA molecules deliv-
ered by intra-peritoneal injection are not affected by
serum derived exonuclease activities [49] and do not
require structural variations or stabilizing modifications
[50] in order to have an efficient local and systemic effect
on the target gene. This approach is effective, non-perma-
nent, technically simple, and avoids some of the side
effects of other delivery and gene silencing approaches.
Conclusions
We have demonstrated in vitro that IL-12p40 siRNA specif-
ically silenced its mRNA homologue leading to transient
silencing of IL-12p40 and consequent knockdown of IL-
12p70 expression. At the doses employed, this was spe-
cific and did not result in detectable induction of type I
interferons. Silencing of IL-12p40 by siRNA did result in a
reduction of IFN-γ production detected by ELISA. These
findings were extended in vivo. Silencing of IL-12p40
results in the non-permanent suppression of IL-12 in a
murine model of peritoneal inflammation. We show that
siRNA can be used therapeutically after the initiation of an
inflammatory response to silence IL-12 expression and
observe a reduction in peritoneal inflammatory infiltrate.
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